- Home
- MYGN vs EVEX Comparison
MYGN vs EVEX Comparison
Compare MYGN & EVEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- EVEX
- Stock Information
- Founded
- MYGN 1991
- EVEX 2020
- Country
- MYGN United States
- EVEX United States
- Employees
- MYGN N/A
- EVEX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EVEX Aerospace
- Sector
- MYGN Health Care
- EVEX Industrials
- Exchange
- MYGN Nasdaq
- EVEX Nasdaq
- Market Cap
- MYGN 1.2B
- EVEX 1.3B
- IPO Year
- MYGN 1995
- EVEX N/A
- Fundamental
- Price
- MYGN $14.18
- EVEX $4.18
- Analyst Decision
- MYGN Hold
- EVEX Strong Buy
- Analyst Count
- MYGN 13
- EVEX 3
- Target Price
- MYGN $22.54
- EVEX $6.00
- AVG Volume (30 Days)
- MYGN 1.2M
- EVEX 197.9K
- Earning Date
- MYGN 02-24-2025
- EVEX 03-07-2025
- Dividend Yield
- MYGN N/A
- EVEX N/A
- EPS Growth
- MYGN N/A
- EVEX N/A
- EPS
- MYGN N/A
- EVEX N/A
- Revenue
- MYGN $823,600,000.00
- EVEX N/A
- Revenue This Year
- MYGN $13.60
- EVEX N/A
- Revenue Next Year
- MYGN $3.25
- EVEX N/A
- P/E Ratio
- MYGN N/A
- EVEX N/A
- Revenue Growth
- MYGN 12.15
- EVEX N/A
- 52 Week Low
- MYGN $12.04
- EVEX $2.33
- 52 Week High
- MYGN $29.30
- EVEX $6.09
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- EVEX 39.23
- Support Level
- MYGN $14.13
- EVEX $4.36
- Resistance Level
- MYGN $15.47
- EVEX $5.04
- Average True Range (ATR)
- MYGN 0.72
- EVEX 0.29
- MACD
- MYGN 0.27
- EVEX -0.05
- Stochastic Oscillator
- MYGN 61.38
- EVEX 0.58
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About EVEX Eve Holding Inc.
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment , a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.